Department of Pediatrics, University of Pennsylvania, Vaxconsult, Doylestown, Pennsylvania, USA.
Merck & Co., Kenilworth, New Jersey, USA.
J Infect Dis. 2020 Mar 5;221(Suppl 1):S113-S122. doi: 10.1093/infdis/jiz447.
Numerous candidate vaccines against cytomegalovirus (CMV) infection and disease are in development. Whereas the previous article [1] provides background and opinions about the issues relating to vaccination, this article provides specifics about the vaccines in active development, as reported at a National Institutes of Health-sponsored meeting in Bethesda on September 4-6, 2018. Here, vaccine developers provide synopses of their candidate vaccines to immunize women to protect against congenital CMV disease and to prevent the consequences of CMV disease in recipients of transplanted organs or hematopoietic stem calls. The projects are presented here roughly in the descending order of their stage of development in the opinion of the first author.
目前有许多针对巨细胞病毒（CMV）感染和疾病的候选疫苗正在研发中。上一篇文章[1]提供了与疫苗接种相关问题的背景和观点，本文则根据 2018 年 9 月 4 日至 6 日在马里兰州贝塞斯达举行的美国国立卫生研究院（NIH）会议的报告，提供了正在积极研发的疫苗的具体信息。在这里，疫苗开发者概述了他们的候选疫苗，以保护女性免受先天性 CMV 疾病的侵害，并预防接受移植器官或造血干细胞的患者发生 CMV 疾病的后果。本文中的项目按第一作者的观点大致按其研发阶段的顺序呈现。
